ITERIUM THERAP. EO-,01

Iterum Therapeutics announced that its common shares will be delisted from NASDAQ and trading will be suspended at market open on April 1. The delisting follows the withdrawal of an appeal against a prior delisting order for failing to meet the $1.00 per share minimum bid price requirement. The company initiated liquidation proceedings in the High Court in Ireland and said it intends to withdraw the appeal. Due to limited available cash and the ongoing liquidation proceedings, Iterum does not expect to file its annual report for the year ended December 31, 2025, or further documents with the SEC. » More on de.investing.com

Iterum Therapeutics has requested a hearing before an independent Nasdaq committee after being notified on Feb. 24 that it failed to meet the required minimum bid price of $1.00 per share. The planned suspension of trading and delisting scheduled for March 5 are temporarily stayed by the hearing request, but a favorable outcome is not guaranteed. The company also does not meet Nasdaq Rule 5550(b)(2) for the $35 million minimum market value and has until June 9, 2026 to regain compliance; Iterum is evaluating strategic and financial alternatives, including sale, licensing, a transaction or winding down. » More on de.investing.com

Iterum Therapeutics reached a rebate agreement with one of the three largest pharmacy benefit managers for Medicare Part D that enables inclusion of ORLYNVAH on Medicare formularies and could potentially reach more than 3.5 million beneficiaries. Reimbursement is expected to begin later this quarter, completing agreements with all three leading PBMs for Medicare Part D. Iterum also received U.S. patent 12,544,337 for a two‑layer tablet (sulopenem etzadroxil/probenecid) extending to an expected December 2039; the FDA requested additional clinical evidence for a step‑down indication and recommended a Type C meeting. » More on de.investing.com